Verrica Pharmaceuticals Inc. (VRCA) Investor Relations Documents

Verrica Pharmaceuticals Inc. (VRCA) investor relations documents from the company's IR site: 1 presentation, 14 press releases; latest deck 2026-05-13. Read in-app with summaries. First-party data.

https://verrica.com/wp-content/uploads/2026/05/Verrica-Corporate-Overview-05132026-1.pdf: Verrica Pharmaceuticals is a dermatology company commercializing YCANTH for molluscum contagiosum, with 2025 product revenue of $15.3 million, up 130% year-over-year.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseVerrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
2026-08-06Press releaseVerrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
2026-08-06Press releaseVerrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
2026-07-21Press releaseVerrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commerci
2026-06-22Press releaseVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3
2026-05-13Press releaseVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
2026-05-13Presentationhttps://verrica.com/wp-content/uploads/2026/05/Verrica-Corporate-Overview-05132026-1.pdf
2026-05-12Press releaseVerrica Pharmaceuticals Reports First Quarter 2026 Financial Results
2026-05-05Press releaseVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of V
2026-04-09Press releaseVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315
2026-03-11Press releaseVerrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on
2026-03-11Press releaseVerrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-12Press releaseVerrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
2026-02-09Press releaseVerrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii
2026-01-07Press releaseVerrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment o

VRCA overview · VRCA earnings · VRCA financials · VRCA KPIs · VRCA ownership · VRCA peers · VRCA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.